Best of ASCO - 2014 Annual Meeting

 

Welcome

Neuroendocrine/Carcinoid

Gastrointestinal (Noncolorectal) Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase I/II study of fosbretabulin in combination with everolimus in neuroendocrine tumors that have progressed after at least one prior regimen for metastatic disease.

Aman Chauhan

TPS4148

A phase I/II study of the combination of temozolomide (TM) and pazopanib (PZ) in advanced pancreatic neuroendocrine tumors (PNETs) (NCT01465659).

Manali A. Bhave

4096

A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).

Pamela L. Kunz

4004

Additional value of tumour growth rate (TGR) in patients (pts) diagnosed with well-differentiated neuroendocrine tumours (NETs) achieving RECIST-defined stable disease (SD): Subgroup analysis of the GREPONET study.

Angela Lamarca

4094

Assessing prognosis of neuroendocrine neoplasms: Results of a collaborative multinational effort including over 10.000 european patients—The ENETS registry.

Ivan Borbath

4095

Azedra (iobenguane I 131) in patients with malignant, recurrent and/or unresectable pheochromocytoma or paraganglioma (PPGL): Updated efficacy and safety results from a multi-center, open-label, pivotal phase 2 study.

Daniel Pryma

4005

Capecitabine and temozolomide (CAPTEM) for intermediate to high grade metastatic neuroendocrine tumours (NET): A single centre experience.

Arvind Sahu

e16159

Clinical outcomes in patients with baseline renal dysfunction in the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.

Jonathan R. Strosberg

4102

Clinicopathologic features of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): A single-center experience.

Tugba Akin Telli

e16168

Clinicopathological characteristics and prognosis of gastrointestinal cancer with neuroendocrine differentiation.

Meili Chen

e16161

Comprehensive genomic profiling of 724 gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Alberto Puccini

4098

Efficacy and prognostic factors for y-90 radioembolization (Y-90) in metastatic neuroendocrine tumors with liver metastases.

Erica S Tsang

e16180

Efficacy of 2nd-line chemotherapy in patients with poorly differentiated, high grade extrapulmonary neuroendocrine carcinoma (PD NEC).

Patrick Walsh McGarrah

e16162

Evaluating survivin as a potential target in neuroendocrine tumors (NETs).

Ahmad Hanif

e16171

First in human phase 1/2a study of PEN-221 somatostatin analog (SSA)-DM1 conjugate for patients (PTS) with advanced neuroendocrine tumor (NET) or small cell lung cancer (SCLC): Phase 1 results.

Melissa Lynne Johnson

4097

First update on overall survival, progression-free survival, and health-related time-to-deterioration quality of life from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors.

Jonathan R. Strosberg

4099

Health resource utilization among patients with metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) treated at a tertiary referral center.

Jie Meng

e16177

Impact of Ga-68 DOTATATE scan on clinical management of neuroendocrine tumor patients (NET): A single center review of 200 Scans.

Aman Chauhan

e16187

Impact of multidisciplinary management in the diagnosis and treatment of neuroendocrine tumors.

Anuradha Krishnamurthy

e16165

Lanreotide depot/autogel before, during, and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumors (NETs): Data from the PRELUDE study.

Vikas Prasad

e16167

Metastatic neuroendocrine neoplasia treatments in patients over 70 years of age: A retrospective outcome analysis.

Alberto Bongiovanni

e16181

Multicenter phase 2 study of nintedanib in patients (pts) with advanced progressing carcinoid tumors.

Renuka V. Iyer

4105

Neuroendocrine carcinoma of luminal gastrointestinal tract.

Mahvish Muzaffar

e16186

Optimal cut points for Ki-67 proliferative index in predicting survival in high grade neuroendocrine tumors.

Robert A. Ramirez

4103

Pancreatic exocrine insufficiency (PEI) secondary to chronic use of long-acting (LA) somatostatin analogues (SSA) in pts with neuroendocrine tumors (NETs): Pooled analysis (USA and UK).

Wasif M. Saif

e16166

Pembrolizumab (P) monotherapy in patients with previously treated metastatic high grade neuroendocrine neoplasms (HG-NENs).

Namrata Vijayvergia

4104

Pembrolizumab-based therapy in previously treated high grade extrapulmonary neuroendocrine carcinomas.

Claire Hooker

TPS4147

Peptide receptor radionuclide therapy (PRRT) transcriptomic signature in blood for prediction of 177lu-octreotate efficacy.

Lisa Bodei

4101

Peritoneal carcinomatosis (PC) in well differentiated small intestinal neuroendocrine tumors (SI-NET).

Satya Das

e16164

Prognostic factors in nonfunctional well-differentiated gastroenteropancreatic neuroendocrine tumors: Single Institute Experience.

Mutlu Dogan

e16176

Prognostic significance of tumor-associated macrophages in pancreatic neuroendocrine tumors.

Alejandro Cruz

e16178

Racial differences in the incidence and survival of patients with neuroendocrine tumors (NETs).

Amir Mehrvarz Sarshekeh

e16175

Risk of health-related quality of life events and pulmonary toxicities in patients with advanced neuroendocrine tumors treated with everolimus: A meta-analysis of phase 3 randomized controlled trials.

Kyaw Zin Thein

e16185

Risk of hematological and gastrointestinal toxicities in patients with advanced neuroendocrine tumors treated with everolimus: A meta-analysis of phase 3 randomized controlled trials.

Anita Sultan

e16184

Systemic immune-inflammation index and neutrophil to lymphocyte ratio for predicting tumor grade in neuroendocrine tumors.

Idris Yucel

e16179

The epidemiology of carcinoid tumors of small and large intestine in USA: A national inpatient sample analysis (2009-2014).

Nauman S Siddiqui

e16188

The relationship between Ki-67 index and prognosis for patients with well-differentiation gastric NETs.

Ivan N. Peregorodiev

e16160

The role of Ki-67 in determining optimal chemotherapy in high grade neuroendocrine tumors.

Katharine Thomas

4100

The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Wasif M. Saif

e16174

Treatment outcomes of patients with mixed neuroendocrine-nonneuroendocrine neoplasms (MiNEN).

Leonidas Apostolidis

e16163